Insulin resistance is a condition in which muscle, fat, and liver cells respond poorly to insulin, requiring the pancreas to produce more insulin to keep blood glucose controlled. Persistent insulin resistance can lead to prediabetes and type 2 diabetes when pancreatic compensation is no longer sufficient.
BrightGene Bio-Medical reported Phase III data for BGM0504 showing 19.3% mean weight reduction and improvements in blood pressure, lipids and uric acid. The data highlighted GIP as a key variable in broader metabolic management.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Researchers have used a machine learning model called AI-IR to demonstrate that insulin resistance is a risk factor for 12 types of cancer. The tool analyzes nine clinical parameters from standard health checkups to predict insulin resistance at population scale. This provides the first large-scale evidence linking insulin resistance to multiple cancers.
GLP-1 receptor agonists like semaglutide and tirzepatide help regulate appetite and improve satiety for medical weight loss. Clinical studies show patients can lose an average of 15% of body weight with these treatments. These medications are suitable for individuals with BMI of 27+ with weight-related conditions or BMI of 30+ regardless of other conditions.
Veru Inc. has enrolled the first patient in its Phase 2b PLATEAU clinical trial evaluating enobosarm combined with semaglutide for weight loss in older patients with obesity. The study will assess enobosarm's ability to preserve lean mass and physical function while augmenting fat loss.
Semaglutide reduced osteoarthritis progression in obese mice through metabolic reprogramming of cartilage cells, independent of weight loss effects, according to research published in Cell Metabolism.
A new study suggests 7 hours and 18 minutes of sleep may be optimal for reducing insulin resistance risk. The research found an inverted U-shaped relationship between sleep duration and glucose metabolism, with weekend catch-up sleep showing mixed effects.
Three GLP-1 weight-loss drugs—semaglutide, tirzepatide and retatrutide—reduced weight and improved metabolic health in mice lacking the MC4R gene, offering potential treatment for rare genetic obesity.
GLP-1 receptor agonists like semaglutide and liraglutide may improve fertility through metabolic benefits but are not recommended during pregnancy. Current guidance advises discontinuing long-acting agents at least two months before conception.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599072 |
PREdiabetes GLycemic Impact and Data Evaluation |
RECRUITING | NA |
| NCT07565727 |
Cardiometabolic Disease and Substrate Metabolism |
RECRUITING | |
| NCT07551960 |
Pilot Validation of the STELA Preventive Medicine Platform to Reduce Modifiable Health Risk Factors in Adults (CPM-STELA) |
ENROLLING_BY_INVITATION | NA |
| NCT07551947 |
Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation (HOMA-PULSE) |
ENROLLING_BY_INVITATION | |
| NCT07545538 |
Carbohydrate Loading in Lowering Perioperative Insulin Resistance in Pediatric Surgery |
ENROLLING_BY_INVITATION | NA |
| NCT07516509 |
Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance |
NOT_YET_RECRUITING | |
| NCT07505745 |
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity |
RECRUITING | PHASE2 |
| NCT07494084 |
Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance |
NOT_YET_RECRUITING | PHASE4 |
| NCT07486557 |
Cistanche Deserticola Extract Combined With Aerobic Exercise Improves Body Composition, Insulin Resistance and Inflammation in Men With Central Obesity |
COMPLETED | NA |
| NCT07483723 |
Glucose Profiles in Women With Polycystic Ovary Syndrome |
RECRUITING | NA |
